EOLS - Earnings call transcript Q1 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Please go ahead.

Nareg Sagherian

Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' first quarter 2024 financial results.

Our first quarter 2021 press release is now on our website at evolus.com. With me today are David Moatazedi, President and Chief Executive Officer; and Sandra Beaver, Chief Financial Officer; [ Louis Avelar ], Chief Medical Officer and Head of R&D, is also with us for the Q&A portion of the call.

Before we begin our discussion, I'd like to note that during our call, our prepared remarks will include forward-looking statements within the meaning of United States securities laws, and management may make additional forward-looking statements in response to your questions.

Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which may affect the company's business, strategy, operations or financial performance. no to only reliance of all as and company not statements, these this forward-looking cautioned or the speak update required which of undertakes statements, are except place estimate, by on undue forward-looking call, review as Listeners any to law. projection obligation the date be number statements uncertain and inherently are and of These are and on forward-looking assumptions that, to a reasonable, estimates based although risks uncertainties. believed to subject the XX-Q of company annual X-K. discussion A reports the in XX-K, uncertainties that on is risks its faces detailed report quarterly and contained reports and Form Form on on Form current

Additionally, today's today Investor release, GAAP which reconciliation found Form of not be and as earnings should discussion a results our X-K evolus.com. in filed GAAP substitute our SEC to Relations on results. website which A non-GAAP the in will may our non-GAAP measures, for be was in from to our financial considered with and addition or with at furnished include isolation

Following a website the to be CEO, turn I'll David will call, call our the replay today's evolus.com. With that, our Moatazedi. at on available of conclusion over

David Moatazedi

first Thank afternoon, us our you conference everyone. quarter call. XXXX for you, on earnings joining Thank Good Nareg.

which XXXX, the in year our in record the a third year as represented neurotoxin Following fastest-growing U.S.

pleased growth. adoption very of above-market revenue strong Jeuveau to continued are report the of We and with another performance quarter

and the prior from our $XXX million our $XX.X of momentum revenue guidance net achieving of highlighting million in growth the year, reported XXXX between over represents strength Our and toward quarter in first continued million. XXXX increasing execution $XXX revenue XX%

expense us on the than the clear focus to on rate quarter profitability year. to operating of maintain We operating less expense putting this a half of discipline fourth pathway in a revenue, at continue growth with

growth number of approximately with XX,XXX are that number the treated the the total consumer choosing over metric customers cosmetic building the roughly customers in neurotoxin. The loyalty launch with are customers purchasing a which to penetration consumers is treatment. approximately U.S. who Evolus. XXX,XXX the which I'm and our underscore an consumers XX% who achieved These acceptance. results results share to gaining increasingly with the high our of this new U.S., and to Our the delivered accounts of redemptions, metrics in purchasing quarter represents company feeded our the Evolus added the increased that pleased XX,XXX, who of number XXX in to performance over of continued we bringing brand approach inject since of received differentiated importantly, our loyalty program, partner standout all-time you consumers was quarter. In

to Importantly, XX% treatments of remainder were Jeuveau. repeat and the those were new

loyalty $XX which their continues a loyalty savings program treatment, in in over programs to the meaningful earning Jeuveau consumer Our off every market gain toxin with momentum the is space.

dermal novel On R&D to on the with and launch the in deeper while our international a actively Italy, track to Australia U.S. international later expand our international remain footprint the Spain for U.K., side, we side, this and and continue progress we've on in XXXX. significant development preparing Germany line launch filler lastly, with penetration focus the made of and year. And on in

on their company. team It mission believe [ is at driven, Evolus. the commitment beauty ] building line scale first X at Evolus our meeting days, focused the will results of the market. Friday, file top Nashville. I'm Within next XX, of plan an outsized proud gives we in in to and this the present May of XX our the that a highly presence performance and FDA pillars trial the with They're pivotal in

toxin from procedure. to driven the remains continue healthy high prioritize strong a on recognition on brand well performance market underlying entering allow continued XXXX. to by in [ our us as consumers Jeuveau's is This new demand the to Evelise success commercially clinical penetration continue starting capturing it is consumers generation Our will the filler novel for becomes quarter available satisfaction which ] while positioning largely younger integrate their and market profile when we in the spending line our positioned dermal category. actively prepare

XXXX. of in of remain the Looking least is Nuceiva beyond and achieving fillers the XXXX, beginning $XXX revenue the long-term This international U.S. confidence our by line market expansion Evelise value drive of total we of shareholders driven confident the commitment in strong our million at net our XXXX. by Jeuveau to opportunity in of commercialization the for by goal

Now will financials. I'll who over to turn cover the Sandra, it

Sandra Beaver

I team [ represent spot for Evolus achieving top results The operating Thank of ] would and discipline. guidance quarter another sales a the you, and David. QX towards for our step profitability expense meaningful QX like above-market market line to delivering XXXX. growth congratulate

first the net for reorder of results. up U.S. contribution revenue Turning more approximately pricing the Global $XX.X the first will remains continue U.S., outpace rate growth XX% comprised this toxin to increase environment at as quarter XX%, International revenues U.S. the Sales our higher XXXX. and remains primarily the than In revenue to of were where strong, will net driven volumes. sales international the the in by our in customer quarter quarter. compared to XX% revenues were million,

XX.X% full which first gross excludes margin, Our our intangibles, amortization quarter line reported guidance. in for year was was the of XX.X%, with adjusted and gross margin the and our

the and were in expenses selling, quarter the million operating to quarter. fourth for Our compared million, the GAAP quarter. Reported the first quarter $XX.X quarter. fourth $XX.X expenses general recorded for $XX.X in prior in the $XX.X first were Non-GAAP were $XX.X to to compared compared administrative million million the quarter first million million for operating expenses $XX.X

launch million filler in operating the $X.X noncash in throughout levels. expenses of We our we million anticipate with included QX compared compensation year fourth expenses XXXX. as increases line prepare modest SG&A quarter, $X.X in remain This to stock-based to expense quarter. Operating the the begin for spending

million operating fourth quarter. quarter the non-GAAP million to operations This Our from the the from $X.X expense, sequential quarter million operations and and in of loss from $X.X non-GAAP XXXX. of obligation a expenses meaningful in in depreciation the in first loss compared our improvement amortization. revaluation reported represents continued compensation non-GAAP was loss operations $X.X royalty Both fourth on path the stock-based excludes contingent non-GAAP towards progress and profitability

to offering XX, was operating timing payments. of QX the cash net due quarter use flow $XX quarter continued Turning the represents the of million in balance This compared use year-over-year balance the used sheet. annual first includes December in that which The note operating million ended XXXX. It's for March. progress cash to quarter to at improved operating cash from is million $XX.X Net with proceeds to underwritten in $XX million, We activities reduction first $XX.X compared million bonus breakeven. $XX the important to the as cash highest seasonally cash towards cash XXXX.

profitability of XXXX. continue existing in debt fully fourth fund We XXXX to full us for expect $XXX quarter the the will liquidity million XXXX and our year beyond, including XXXX, facility and our to repayment of

have $XXX year. we on continue evidenced our as quarter to confidence to track results revenues announced and Jeuveau in $XXX performance in of million as earlier are deliver the million this We by to first strong

contribution in Total to total that revenues by begin will to summarize which I'd XXXX, share to international $XXX approximately XX% of of to annual equates million the a billion that XX% growing like and $X revenues in in from the target our over markets, [indiscernible] novel context XXXX. fillers of net of from on our mind, U.S. by along $XXX guidance. a our U.S. driven rate market by neurotoxin from addressable line least today, total continue growth in $XXX international approximately continued XXXX. With the business and at We million of between sales million This of compounded growing the and come $XX in with growth markets. balance in million,

Our seasonality. quarterly typical industry revenue assumes

expect second growth expense of $XXX operating In first noting million compare rate, growth in by period. range primarily gross million. is the adjusted $XXX half addition, worth to margin to rates it in and guidance XXXX XX% exceed half XX%. Non-GAAP we between the driven And that

noting on to sustained consolidated due income filler for the to XXXX. profitability We may non-GAAP and also quarter year the XXXX, worth basis full within year be expect fourth a the It launch. that is of quarter positive achieve every XXXX not operating the

company can XXXX. reach by revenue million least net total the $XXX at projected Finally,

turn Now let to the me call back begin to the Q&A. operator

Operator

the comes [Operator of Samimy Stifel. from first line question Our Annabel Instructions] with

Annabel Samimy

on Congratulations strong another quarter.

lot new wider. just I level? Do to is XXX guess, I I'm So deeper account a to it addition up Obviously, sort the wondering from is second, it's picked wanted ask first, momentum. bit account you guess quite go you sustainable? in is, room of it And necessary? and what than have I And you're a about XXX, a

as then, of on you getting not you're deeper So one you I if picture X still some get accounts quarter, how to the reason accounts. And can may guess, into thoughts your drive another, or dynamics bigger see market many for additional as think those about touched closer. and and on market. now starting the Galderma it it I shift know ] themselves. to is it's we're coming we've entrants closer to -- before, public coming And becoming it's but some [ speaking

I about So in playing U.S. how to out. And they more things proxy as a of evolve how we market use you options there. lot I are dynamics guess, the feel a see kind going then Europe given to just have wanted for product over can

I'll guess that. I with So start

David Moatazedi

go up on through starting them And about the new Annabel, XXX to each the Great. through, XXX. questions. you went over new to accounts now consistently step-up for XXX. been X just we've as see and of we're around with mentioned, thanks I'll just accounts. Look, years in really in thrilled as the from average, you last

we north target as in for a we accounts. past, the new have Ideally, XXX. we think stated it's I stated don't of as

what with increased getting quarter demand we're up it's demand influx new I to per threshold, of just in driven to that want by Evolus. the think XXX accounts new you're in accounts partner the seeing largely this

it around And of As are imagine, driving of consider both are the to in continues that our our new media partnering and can the brand you level company increases us. those noise more accounts as quality with program, consumers are our and more perform as the loyalty to product, co-branded catalysts increasing. all the

as coming as our existing back, from customers. to the and think the going because of in launch we penetrated And total base only about our of so the your that there spend quarters of existing more future, where a may in we majority not they us go and may much accounts are be be new especially important believe allow accounts. to But that it these account with sustainable but may with onion time into our accounts the spend growth is market, within I we the new time filler XX% the peel opening able retrench sense deeper point, wider in the XX,XXX. To we're the

So a be XXX have think overall, our penetrate the deeper going wider And well rates growth I that confident. would whether forward as We of that in accounts, composition very anywhere in order very going XXX as market. we in with cadence healthy business range. healthy our going feel to business or the is

And but And accelerating Look, in build it we Evolus. And going generation years, on was a as market market. you guidance. in right? growth of something market. takes product these in fifth factored younger that mind pay our capabilities, position in focus In currently and when that's our back positioning. -- a against entrants. anticipated Europe. know, As year-end, saw to the they they're this that that, over Moving value feel that half the unique into the time. that's end, our partner over customers to Earlier then and with this you confident market Not year, we looking entering year beginning year. one year was build year, we've were this a the product approved. defined additional that new just about where the over we've now strategy, FDA the you partnership anticipate brand front compete to to partnership and those is and that in the with on continued Keep enter before its our see time market this entrants cash with we last this we of the and other

is there younger on I the be we positioned So new there market like fillers. And brand think high-growth you very where by generation. Then down we market get growth in tailwinds and and then focusing feel are see benefit the other without players. good the more will as markets are just that markets affecting of our competitors that these think about enter, the road existing can they and I in entrants that

came that in the I think our evidenced latest and that business perform by to was well. entrants continued

world good some degree, where Western that I is proxy. So we to about think the feel are on a we side. And

one. an So Europe is unreasonable not

dynamics. there For the are U.S., similar

look predictor the think I So in think closely is we where at a to opportunity we be do of Europe the U.S.

Annabel Samimy

could I differently about be just you there kind can dynamics of than more performance enter of in. if market? should market? stellar And anything the market? a one Is we trends the you What performs this tell kind Okay. bit that Obviously, what in it should as market. little we expect squeeze And about neurotoxin just thinking us

David Moatazedi

market. Well, at a you valued about the the have size market toxin that's of X/X of

value that $X.X the make growth It's healthy we Hyaluronic of anywhere trends and XX% had very U.S. the filler that, will a acids up So market XX% over in a category. time, to. it's total billion from continue of expect to market has

just the that of of positions as we very think, space. a families us I one being Evolus so U.S., few fillers, enter enters once well And

something it's as it's think watching, that it growth create catalyst, opportunity it's GLPs is to meaningful in the largely fully it also to that a very near function rates. catalyst we not of the you And healthy a before a historically, filler at that market we time we're mid- see with for timing yet. baked relates a but forward. that over a is be believe looming be market if that there but growth I We market look think that's the going start category that closely just does high to toxin And will single-digit

Operator

comes the question from Marc line of Leerink. Goodman with next Our

Marc Goodman

AbbVie, the David, of the that And in can and first overseas little think markets can is there? the talk the And in numbers you Europe? you you grew the extension what you're maybe quarter? what in a to market you as thought some previous numbers did just about U.S. growth the the then How talk bit from participating key Galderma of question.

Sandra Beaver

much Thanks so Mark, for the it's question. Sander here.

that notably markets the for when are other still Europe. Europe. the growing of on as we're for deeply a Italy that our in share much in overall confidence we it sort might on read which we at gives of terms clarity most the We performance for the the healthy It makes market, is one as Hard go. But health new a are the into like market. As an get rate growth relates above but and market us in last through companies it to harder year how of at to in a quarter, here we of to and believe days penetrating into triangulate in demand our full entered and healthy on continued significantly benefits significantly think as more growing having reporting that newer U.S. relates Europe U.K. competitor growth underlying we those can't what to you're yet any one a entered into entrant than product a the as markets market, a number back is first, precise a us hearing higher and so what market, the there's we more to us see gives growth. growing. rate, it still there many market, that's little indicated certainly more we in of as that obviously, for continues one by particularly expect that the this market, in market the reporting. did entering earlier a is underlying It new what you're and of overall very us us to I little is, those growing to market to and half to be be market these We're the

David Moatazedi

maybe And Canada. U.S. add is at market track the Europe very and we and thing other closely the the only look launch, each like analogs I'd

terms the about new are the confident we're the keep dynamics entering. But feel of between we're and we out significant Europe difference. States getting pricing the in mind, So of really pretty in uptake United markets these

factors values so And what respective that's of markets. the into the

Marc Goodman

loyalty talked same the about the last $XX the quarter that on Is was certificate. going You U.S., customer in that as well? that thing

David Moatazedi

Yes, offer, years launched that's continued we've part of our that and Rewards off consistent which program is to every several Consumer for we've Evolus our about ago, be $XX consumer.

you're is consumers. them So it's for can to every on that traction what's the you to been increased in offering for visit. the when seeing $XX on a multiyear meaningful Mark count in think $XXX That savings for for multiple effort. these driving about point. treatment years market. off consistency That's When a a consumers these they $XXX $XX really

Operator

of Our next Ty the line question Paribas. Navann comes from with BNP

Navann Ty Dietschi

I U.S. A on if competition, may. follow-up toxin

If then of of offering? differentiation in terms you million new could your could for discuss 'XX ] the separately, [ XXXX $XX of uses -- discuss 'XX you proceeds outlook price, and timing for the and potential the opportunistic assumptions And entrants? if

David Moatazedi

take Great. see let the of we Navann. We're marketplace. Look, later year. product very around the last think portion this start Thanks I the expected well new proceeds. the question, the a Sandra use for I'll of the with coming entrant aware to profile. I'll in

rather comment competitor. point, think any at I on one this than

new expect to to I important note we address comes entrant and as this think that that we'll growth. in. Probably be market each healthy

that you new entrants. year this that we're million, achieving share. going forecast forecasted our at have market That also gain entry. assumption new XXXX, We several assumes market to And when assumes look a $XXX

for do to their own do new us proposition to the value and unique same. So in out entrants and an carve continue for opportunity think I there's come to

what and we consider As how not each or do. it may entrant to may new relates we

with in SAP we'll things types after you think ] are the advance. the I probably that [ sharing those be of versus

Sandra Beaver

question have we raise specifically stock. from as relates felt to on was beyond. raise, profitability to confident before and the it the demand due cash we said has ourselves carry our through changed as to for sufficient and inbound since we liquidity your and nothing to proceeds Navann, high very raise The the

we would have give sheet balance opportunity hand, when nothing where deal have And to of we sheet able to And incredibly there the us get healthier continue could had we deal up there's balance opportunities. Having capital-efficient us. time see portfolio an Evelise with reason opportunities. moment do saw moment opportunistic on cash pursue our front a that and much our said those consider ourselves ability that which be could position been We you new invest. we be opportunistic with should an the capacity no stock. to we shore an expand is to in a the like incremental now that limited in to to imminent into strategic in There's why was it investors really in the event

Operator

with Ear question next the Our Uy line from Securities. Mizuho comes of

Uy Ear

the a question and So second the larger may breadth the fillers? and question. And is do question like colors some is, what have expect to Just can around derma the in Maybe the dollars average proportions see width what when first you little should expectations. we the share account dollars? just per of a accounts. you present of to digging for the terms deeper first That's speak -- data at maybe

David Moatazedi

Great.

right? I So the XX,XXX account. customers market. it, with dimensionalize think value to let the just report Look, U.S. me I think start But don't per in out we the just on

a of to there, that rule -- sort You customers apply about you And there's better roughly. an understanding the could category. simply of get XX,XXX XX-XX see from

long XX-XX represent did rule you an the If tail. that

to some in the today. smaller the smaller be are the then XX% are dabbling driving roughly either that just biggest more clearly, the those treating of of or lot majority of smaller ago customers now we of that number patients. And U.S. the have customers out throughout X,XXX But revenue. to several our years So value remaining try there take are aesthetics the some large to And on preference value value the would customers customers. it, customers highest certainly reality, ones a newer call and in a or aesthetics are

new of So properly I you've advantages each as to support the cash we existing that patients think methodically into seen of these penetrate unique of we'll that attracting the brand practices practices a this we then offer. market are XX,XXX continue on whether gets And some generation performance introduced that their and switch practices the and accounts beauty think they're these younger to I Jeuveau of more to and it, Jeuveau category. pay our train quarter overall differentiation or

think to ways many pie. this there's I grow

out, of and may we overall We're look about very there's to this of we're in we XX% in estimate be ways on capitalizing I both. dollar the the many think feel grow value as roughly dynamics So but we market, in we good approximately XX% toxin accounts, of market. that the

rough estimates, are gauge how estimates, of in they're but these that course, we're tracking. gives a terms Of you

Unknown Executive

that for respect late-breaking filler, second the question, use, for it's allows the with a format there's And to scale [indiscernible]. at called

So place XXth. take on the the at that end will of the day

select with line of in safety to So and late-breaking snippet the just and results secondaries kind news, can to see profile conclusion. some the quick of keeping a you expect then top

David Moatazedi

And provide time, prepared color commercialization more efforts. not this we're our at on to

provide we we'll that the think approval. into closer after launch date and get FDA I as

Operator

with Wainright. question of comes next H.C. the Douglas line Our from Tsao

Douglas Tsao

the market, market the the continues of obviously, of as aren't the fact you performing as as of would that well right It a necessarily given how you're participants. But that is broader any the you highlighted stage you as to or some your broader Are at the growth dynamics now sort than different on tactical they seem players changes? that competitive market. making doesn't on and characterize well just some everyone kind be same progress. experiencing are, think the Sandra I that Maybe and necessarily the healthy. Congrats belief you

David Moatazedi

Yes.

the made and single-digit be We feel very to this had would year we healthy the market have here. high So we around confident I that in growth. mid- comments think forecast market, roughly a we this broader

we X see. years And to coming there's speak fairness, to the X out quarter don't first as over any more trajectory what we The to parts to expected all is see of any want frankly, quarter moving likely that because within think XXXX. I lot confirmatory company. I one competitor on guide the in we is a

So every not year category some deliver at toxin in of looking this I'd except look, the player there, of go to level we that, if the this because have overall, a to growth I healthy I'd rather say were expect space backdrop market.

consumers think demographic perhaps this the contribution the consumer on positioning is to seeing differentiation our positioned, the continue growth we function share we positioned that of recruit that are office sustainable the our for to category. extent new received that, younger that, as think hard the of and that that the catalyst growth. And believe against and I it's a where our is and brand this in to to growth this gains, over-indexing that our further grow you're can a a And and catalysts build function receives to go to in us our market. that for that's their that category leads more growth the index way the to order it's we but are on estimate, above benefits to practices driving driver we're

Douglas Tsao

getting would of different be be the much that X and they're segments boomers -- extent the too across Can see? segments procedures. versus granular. the How some might provide hope you do still you aesthetic Gen And I get doesn't you versus how that like variability on the David, perspective growing millennials this maybe those and think sort of market to

David Moatazedi

the we point. approaching see set toxin question, are that a data favorable quarters aside the or our that is majority increase that wouldn't surprised will a one. the set front that of third market have they're expecting us I'm don't we sharing very near from there. That of the Unfortunately, likely answer have with important already I coming concrete millennials in to to that in And mix And Doug. that backdrop in you an continue that a towards party. from millennials. think And I that's Yes. data users be suggests believe could right they're we tipping

when X over ago, the because company. what this I forward starting benefits where category, of to the years the thinking going think positioning years. a whole importantly, as given company for category about the launched us, frankly, positioned X next fuel see we're to that for But we that's we

Operator

comes Needham question next & of Belanger from Our Company. line the Serge with

Serge Belanger

I quarter growth mentioned first driven was volumes. mostly that think Sandra Juho by the in

stable. very pricing So I assume was

Just your for And it eventually in are terms expectations seeing of European more market the the levels? what this come as what now pricing could competitors on markets front pricing kind in curious replicate of in? we're

Sandra Beaver

modest I'm that the nothing of against price, So to question, has right see inference and the and we very It could see changed see market It's Jeuveau, quality doesn't Yes, We've behave in quarter, how that despite we the on we us that is tend frame decreases continued for terms the right? Thanks in is the performance market. upward that that meaningful price. The it exactly European nothing really in pricing expecting remained to a pricing and of not Serge. is rate stable. differentiate has strength we past, like quality the movement continues strength but us said in U.S. the the of the the really mobility of driven by first position. price. in give not to and increases. ourselves market our products foremost. And on for

David Moatazedi

we look environment advertising U.S. can't is point, ability other what direct-to-consumer do drugs. The dynamics piece drove the our to or different the appetite consumer in the with Europe U.S. a did market Sandra's I'd to to relative in creates some Europe relative you pricing at only to the add of to

loyalty you why of only part very the increase Evolus, that and just competitive the for are programs, we consumer And like despite been past. up these really what think over trends, to reason that's entrants is over years. programs not but offer new seen XX sustainable to ability last Our set believe price the XX over you've in XX over a shift players it, If And several significant you've years. X there's accordingly. it's and we about pick seen today not if we've years, the modeled X more the next

give think to to are primarily, I appreciate the see to deliver nominal very by opportunity and assumptions continue but realistic on price volume amount. potentially So our us some

Operator

comes And question Barclays. our with the Balaji next Prasad line from of

Mikaela Franceschina

on for Balaji. is Mikaela This

Just what further bundling might as we your about line, -- of are color size thinking the how thinking filler about get in implementing you like just launch And strategy sales terms to any look closer force? especially like, of of on here the what your any thinking programs? you're your

David Moatazedi

Thanks Sure. for question. the

potentially process in of the are We would assessing launch next how filler year. approval we actively the upon

earlier, we'll that from a clock, excited signed in last be quarter us we the next will XX of filing this year. with very we're on in the FDA, which which is agreement heard fillers the first very second considering put you exciting, X As the days,

can expand we at opportunity pace launch is also you that, and about to a think the launch, that fact we beyond I a XX,XXX by the Evolus excited customers moving we're there's on can customers an that of expect obviously, base significant but an customers which group us now of have with And that it. is we're since very continue fast. And So launch that we that it's focus from. to partnership will important Jeuveau, one, gives

as That we training. fillers hands-on team that of We but a medical provide capable infrastructure not also have neurotoxins supporting just is significant education, well.

today way designed was through the all In building with company in carries aesthetics. of intention also absorb our than out the product. more co-branded was is infrastructure, portfolio built one which it program, and outset to our Evolus designed to addition from the digital the a to but which that Jeuveau, for

filler, our we in in and that that which the more fillers benefit from number are toxins we addition are that consumers, large comprehensive so purchasing platform from filler. And a a will to will on the addition of know toxin adding us for the consumers entire of which the offering our loyalty program customers expect a gives currently benefit

it's go launch. So of to intersect. as doing get How opportunities we it, we share two for lot see we'll to a something these closer about we

Operator

President time, would Chief Moatazedi, Thank Officer back all the you for like this your for At call to over turn David questions. closing comments. I and to Executive

David Moatazedi

the to unique first the market cash-pay as the a Thank difference quarter brings beauty you. reaffirm focused The results performance Evolus company. of

will remain Our consumer centricity multiproduct outpace building product to a and from single execution, and aesthetics we market. performance us to performance duty above-market to continued customer product strength continue a evolve the enable on momentum innovator. in as laser-focused and company We performance

the journey underscoring profitability, marks towards milestone and a excellence in trajectory, discipline. significant for fourth of year our slated this quarter Our financial our operating

consistently we market As apart. are share setting competitive Evolus within we gaining navigate aesthetics, landscape the and

advantage, progress to I'm value our we've achieve the deliver long-term a the we least in of business forward growth of us portfolio, and With by model, goal at balance our effectiveness look to you keeping sheet, and are remains product sustainable year Our million to and shareholders confident differentiated demonstrated revenue a infrastructure today. solid $XXX competitive strong clear Thank that positioned joining for years as well for apprised for come. We to you our unfolds. XXXX.

Operator

this Thank call. you. concludes today's And

disconnect lines. now may You your

Evolus (EOLS) 7 May 242024 Q1 Earnings call transcript